Global Robot Assisted PCI Market is growing at a healthy CAGR of 36.8% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.
Access Full Report at https://databridgemarketresearch.com/reports/global-robot-assisted-pci-market
The global robot assisted PCI market is a highly concentrated market which includes key players and local players. The market has witnessed increased various strategic developments owing to favourable market scenario. The market has a prominent growth in upcoming years due to rising elderly population, rising case of cardiovascular diseases and better benefits to patients and surgeons.
The market has witness developments in terms of merger and acquisitions, partnerships or product launches to enhance the product portfolio to meet the rising demand of innovative monitoring technology in robot assisted PCI. For instance, In April 2019, Corindus, Inc. announced that they have done partnership with Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital to use first clinical robotic-assisted PCI procedures in Japan. After this partnership Corindus, Inc. is trying to expand their medical advancement to additional markets worldwide. Japan is havingone of the largest markets for robotic assisted PCI.
Corindus, Inc dominated the global robot assisted PCI market. The other key players existing in the market include Robocath, Inc.
Corindus, Inc:
Corindus, Inc headquartered in Massachusetts, U.S. was founded in 2002. The company focuses in robotic-assisted vascular interventions. The company has 90 employees as per of March 8, 2019. The company is continuously engaged in strategic relationship to enhance the product and service of the robot assisted PCI such as,
- In October 2016, Corindus, Inc. announced that they have received approval from the U.S. Food and Drug Administration (FDA) for the next generation CorPath GRX. It is an advance PCI system and after receiving the approval company expands their product portfolio.
It has its global networks through direct sales representatives and distributors in the North America, Asia-Pacific, Middle East and Africa, Europe. The company has subsidiary such as Corindus Vascular Robotics (U.S.).
ROBOCATH, INC.
Robocath, Inc. is headquartered in Rouen, France, founded in 2009. The company is engaged into developing and marketing robotic solutions for the treatment of cardiovascular diseases. The company is continuously engaged in strategic relationship to enhance the product and services of the robot assisted PCI such as
- In February 2019, Robocath announced that their product Rone robotic device got CE certification in the field of interventional cardiology. After getting CE certification, company could begin commercialization in Europe and the Middle East. It is the first European robotic solution to get the CE certification in the field of interventional cardiology.
